INSULIN SUPPLEMENT IN TYPE-2 DIABETIC-PATIENTS WITH SECONDARY FAILURE TO ORAL-AGENTS AMELIORATES HEPATIC AND PERIPHERAL INSULIN SENSITIVITY BUT NOT INSULIN-SECRETION

被引:2
作者
PISU, E [1 ]
DEBENEDICTIS, D [1 ]
BAGGIORE, C [1 ]
DIANA, A [1 ]
MARENGO, C [1 ]
BOZZO, C [1 ]
RENZETTI, A [1 ]
PAGANO, G [1 ]
机构
[1] UNIV TURIN,IST MED INTERNA,CORSO POLONIA 14,I-10126 TURIN,ITALY
关键词
Glucose production; Insulin clamp; Insulin receptors; Insulin resistance; Insulin sensitivity; Secondary failure; Type; 2; diabetes;
D O I
10.1111/j.1464-5491.1990.tb01496.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to investigate the mechanism of amelioration of metabolic abnormalities with supplementary doses of insulin, islet B‐cell function and insulin sensitivity were measured in 10 patients with Type 2 diabetes in secondary failure to oral agents. A small dose of ultralente insulin (0.26 ± 0.07 U kg‐ideal‐body‐weight−1) was added in the morning before breakfast. After 3 months insulin therapy and progressive improvement of metabolic control (HbA1 from 10.5 ± 0.4 to 9.0 ± 0.3 % at the end of insulin treatment, p < 0.001), basal C‐peptide and incremental area during an oral glucose tolerance test were unchanged. In vivo peripheral insulin sensitivity (euglycaemic clamp with insulin infusion of 40, 160, and 600 mU m−2 min−1, respectively) was significantly improved (glucose requirement: to 4.7 ± 1.0 from 3.0 ± 0.6 mg kg−1 min−1, p< 0.05 at first insulin level; to 10.8 ± 0.5 from 9.3 ± 0.7 mg kg−1 min−1, p<0.01 at second level; to 13.3 ± 0.6 from 11.8 ± 0.8 mg kg−1 min−1, p< 0.025 at third level). Basal hepatic glucose production was also significantly reduced (from 4.3 ± 0.4 to 3.3 ± 0.3 mg kg−1 min−1, p< 0.05), and residual glucose production further suppressed after insulin supplement (from 1.1 ± 0.4 to 0.3 ± 0.2 mg kg−1 min−1 after 120 min at 100 mU I−1 plasma insulin, p< 0.05). Specific insulin binding to mononuclear leucocytes was unchanged (from 3.1 ± 0.3 to 3.5 ± 0.3 %, NS). 1990 Diabetes UK
引用
收藏
页码:805 / 809
页数:5
相关论文
共 23 条
[1]  
de Lawter DE, Moss JM, Tyroler S. Secondary failure of response to tolbutamide treatment, JAMA, 171, pp. 1786-1792, (1959)
[2]  
Krall LP, Bradley RF., ‘Secondary failures' in the treatment of diabetes mellitus with tolbutamide and with phenformin, Diabetes, 11, pp. 88-91, (1962)
[3]  
Shen SW, Bressler R., Clinical pharmacology of oral antidiabetic agents (II part), N Engl J Med, 296, pp. 787-793, (1977)
[4]  
Schmeltz R., Wendorff HJ, Field JB., Effect of control of blood glucose on plasma insulin responses to various stimuli in secondary failures to oral hypoglycemic agents and in newly diagnosed, maturity onset, ketosis‐resistant diabetics, J Clin Endocrinol Metab, 46, pp. 519-527, (1978)
[5]  
Groop LC, Pelkonen R., Koskimies S., Bottazzo GF, Doniach D. Secondary failure to treatment with oral antidiabetic agents in non‐insulin‐dependent diabetes, Diabetes Care, 9, pp. 129-133, (1986)
[6]  
Gutniak M., Karlander SG, Efendic S. Glyburide decreases insulin requirement, increases β‐cell response to mixed meal, and does not affect insulin sensitivity: effects of short and long‐term combined treatment in secondary failure to sulfonylurea, Diabetes Care, 10, pp. 545-554, (1987)
[7]  
Groop L., Schalin C., Franssila-Kallunki A., Et al., Characteristics of non‐insulin‐dependent diabetic patients with secondary failure to oral antidiabetic therapy, Am j Med, 87, pp. 183-190, (1989)
[8]  
DeFronzo RA, The triumvirate: β‐cell, muscle, liver. A collusion responsible for NIDDM, Diabetes, 37, pp. 667-687, (1988)
[9]  
Janka HU, Standl E. Hyperinsulinaemia as a possible risk factor of macrovascular disease in diabetes mellitus. An overview, Diabete Metabol, 13, pp. 279-282, (1987)
[10]  
Blackshear PJ, Roussel AM, Cohen AM, Nathan DM. Basal‐rate intravenous insulin infusion compared to conventional insulin treatment in patients with type II diabetes. A prospective crossover trial, Diabetes Care, 12, pp. 455-463, (1989)